Sun, Dec 28, 2014, 4:00 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Oclaro, Inc. Message Board

linsprucker 17 posts  |  Last Activity: Nov 21, 2014 12:24 PM Member since: Jul 23, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Report created on November 15, 2014
    Alexco Resource Corp
    Materials/Metals & Mining-Precious
    USAAXU $0.53 Current Columbine Rating BUY
    As of 06/28/14
    Previous Rating
    06/14/14 HOLD
    AXU has Underperformed the S&P by -75.87 percentage points
    % Sell Hold Buy
    -100
    -50
    0
    50
    100
    Hold Sell Sell Hold Buy Buy
    October 2013 2014
    S&P
    AXU
    Columbine's Investment Approach
    Columbine Capital projects that AXU will
    outperform the market over the next 12 months
    and recommends that investors buy it and hold
    until we recommend a sell. Columbine evaluated
    AXU by comparing the company to its peers on
    the individual investment factors listed below. The
    Factor Impact rating beside each measure
    indicates the significance of that particular
    factor’s ranking to our recommendation. You’ll
    find more about the Columbine Capital analytical
    process on page 3.
    Columbine Recommendation Methodology
    Factor Impact Factor Attractiveness
    Cash Flow is Very
    Attractive
    Positive cash flow gives a company funds for internal expansion, acquisitions, dividend payments, etc. Our evaluation
    looks at a company's cash flow over the past four quarters. Stocks favored by this measure have the highest cash flow
    available for their price.
    Industry Momentum is
    Favorable
    Being in a strong-performing industry can have a carry-over effect that influences the investment prospects of the
    individual stocks. We measure the performance of a company's industry group over the past year in comparison to the
    market as a whole.
    Highest
    Book Value is Very
    Favorable
    Companies with high book values and low stock prices can be considered as cushioned against severe declines by their
    intrinsic liquidation value. We compare the accounting value of a company to its current stock price in the form of a book
    value-to-price ratio.
    Return On Equity is Low
    A measure of the rate of return on the ownership interest of the common stockholders. Return on equity reveals how much
    profit a company generates with the money shareholders have invested. In most sectors higher return on equity is better
    for future stock performance.
    High
    Recent Earnings were
    Neutral
    Exceeding Wall Street's earnings expectations ("surprise") suggests that prospects for the company may be even better
    than expected. Falling short of the expectation (a "disappointment") is often punished by investors. We compare a
    company's EPS announcement for the latest quarter to the consensus earnings expectation.
    Recent EPS Change is
    Very Attractive
    Many investors react strongly to short-term changes in company earnings. We analyze recent changes in a company's
    quarterly EPS compared to its current stock price. This measure favors companies that have produced recent advances in
    earnings at reasonable stock prices.
    Estimate Trends are
    Neutral
    Companies that are the subject of increasingly improving earnings forecasts tend to find favor with investors. We evaluate
    the changes over the past sixty days in Wall Street analysts' estimates of a company's future earnings using measures of
    diffusion, magnitude, and extremes.
    Modest
    Long-Term Earnings
    Growth is Very Negative
    Companies with long-term growth in earnings tend to be financially secure and have proven themselves over time. For
    investors, the critical question is, "How much do I have to pay to get that growth?"We compare a company's EPS growth
    to its current stock price.
    Price Action is Very
    Negative
    The Columbine methodology likes to see confirmation from relative strength when buying. If the firm's financial
    fundamentals are in accord, these companies should continue to perform well. Our measure compares a stock's
    risk-adjusted performance with that of the market over the past year.
    Low
    Forecast Earnings are
    Neutral
    The expected return (in earnings) for the purchase price of a company's stock is one of the most basic measures of a
    firm's intrinsic value. We evaluate potential earning power by dividing the consensus earnings estimates from Wall
    Street's analysts by the current stock price.
    Reported Earnings are
    Very Overvalued
    Undervalued companies, with relatively high earnings for their market price, represent profit opportunities in most
    sectors. We compute an earnings yield measure by dividing the company's most recent four quarters of reported earnings
    by its current stock price.
    Lowest
    PAGE 1 OF 3
    Report created on November 15, 2014
    Alexco Resource Corp
    Materials/Metals & Mining-Precious
    USAAXU $0.53 Current Columbine Rating BUY
    As of 06/28/14
    Comparing AXU to its Industry Peers
    Presenting individual firms on their overall
    measures of valuation (current worth) and
    momentum (rates of change) provides a quick
    visual comparison of companies on these two key
    investment characteristics. Generally, under-valued
    stocks that exhibit strong positive momentum in
    earnings and prices (upper-right quadrant of the
    graph) are the most attractive issues. Investors
    with different objectives, however, may care more
    about good valuation ratings, or just strong
    momentum.
    AXU Alexco Resource Corp
    GPL Great Panther Silver Ltd
    PAL North American Palladium Ltd
    XPL Solitario Exploration & Royalty
    Corp
    AUMN Golden Minerals Co
    Median Stock
    Industry Group
    VALUATION
    MOMENTUM
    BAD MOMENTUM
    OVER-VALUED
    OVER-VALUED
    GOOD MOMENTUM
    UNDER-VALUED
    BAD MOMENTUM
    UNDER-VALUED
    GOOD MOMENTUM
    AUMN
    XPL
    PAL
    GPL
    AXU
    Earnings Per Share
    QUARTERLY ANNUAL
    Year Ended Dec.31 Q3 2013 Q4 2013 Q1 2014 Q2 2014 2014
    Earnings Per Share ($) 0.04 0.01 -0.02 -0.03 0.00
    Comparing AXU to its Industry Peers
    $0
    $1
    $2
    $3
    XPL
    GPL
    AUMN
    AXU
    PAL
    October 2013 2014
    Market Cap. Latest Price
    ($ Millions) ($) Ticker Company
    41.20M 0.53 AXU Alexco Resource Corp
    113.03M 0.74 GPL Great Panther Silver Ltd
    65.44M 0.14 PAL North American Palladium Ltd
    38.07M 0.94 XPL Solitario Exploration & Royalty Corp
    29.69M 0.65 AUMN Golden Minerals Co
    Company Financials
    Valuation Measures
    Book Value per Share $0.00
    Book Value-to-Price Rating 98
    Cash Flow per Share $0.00
    Cash Flow-to-Price Rating 99
    Dividend Yield - close 0.00%
    Return on Equity Rating 60
    Trailing Earnings Yield 0.00%
    Trailing Earnings Yield Rating 26
    Momentum Measures
    12-Month Price Change -56.83%
    Price Action Rating 1
    Industry Momentum Rating 76
    Recent EPS Change Rating 5
    Long-term EPS Growth Rating 22
    Forecast Earnings
    Estimated Earnings Yield Rating NA
    Estimate Revision Rating NA
    Earnings Surprise Rating NA
    Columbine Capital's ratings of company financials are
    expressed as percentiles relative to all US stocks (100 =
    Best, 1 = Worst). For example, a rating of 80 indicates
    that only 20% of US companies are more attractive on a
    given analytical measure
    About Columbine Capital
    Columbine Capital Services, Inc. is an independent
    equity research firm with offices in Colorado
    Springs, Colorado. Founded in 1976 by the firm’s
    president, John S. Brush, PhD, Columbine
    provides quantitative research and consulting
    services to professional money managers and large
    institutions worldwide. Following the firm’s
    philosophy that winning investment strategies are
    based on facts, not theories, Columbine has been
    conducting original studies into the historical
    sources of stock return for decades. This
    knowledge provides the foundation for a
    disciplined, step-by-step analytical process that
    allows direct comparisons between companies.
    PAGE 2 OF 3
    Report created on November 15, 2014
    Alexco Resource Corp

    Sentiment: Strong Buy

  • linsprucker linsprucker Nov 17, 2014 8:18 PM Flag

    Htsounds more like you do not understand balance sheets and income statements o0-q reports with any real accounting understanding at all:item #9 is the essential is most important detail of the 10-q, why? Because it confirms on paper that positive id has already been paid the 2.5 million dollars for distribution and usage rights for m-band testing kit but boeing has to pay royalties for each m-band test-kit. Bio cartridge, and any refils must be exlusively purchased from positive id (psidas mband is reusable. The great news is that the firefly dx -ebola pathogen detector device has not been licensed to any major defeense contractor like boeing: which means that once positive id requests fastrack status for firefly dx and it is quickly granted due to the public demand for a very fast screening of ebola virus psa detection in the patient being paramount in ebola funding and contracts on every level--i look for boeing to license firefly dx usa rights with royalties for each firefly dx purchased and used and boeing will pay positive id a lump sum amount of 100 million in separate yearly installments for exlusive usa distribution so it can get exlusive contract with homeland security for ebola virus detection supplier as positive id and boeing both already research contract agreements with nasa for biological pathogen detecton kits using m-band handheld field tester for future space travel with astronauts on board again being granted to boeing from nasa.

    Sentiment: Strong Buy

  • POSITIVE ID must get a tax incentive for not reporting the already received 2.5 million dollars in fees from BOEING listed as deferred on last qtr earnings and this qtr too--end of year report or 10-K will have to list 2,500,000.00 revenue from BOEING as realized revenue and they still have one more payment due of 200,000.00 from earlier contract fulfilled at end of OCT 2014... HUGE TO SEE ACTUAL REVENUE BEING REPORTED AS INCOME ON THE BOOKS AS IT LEGITIMIZES AND CONFIRMS GREAT LIKLIHOOD OF BOEING/POSTIVE ID BEING A MAJOR CONTRACTOR FOR EBOLA VIRUS testing funding by end of this year.... I predict.....

    Sentiment: Strong Buy

  • linsprucker linsprucker Nov 17, 2014 7:05 PM Flag

    I think that it was a NASDAQ issued 10q for nov 20 press release and not a real time confirmed release date from PSID as you can see by their expected filing date for their 10q before NOV 19--another qtr of revenue for POSITIVE ID though was the great news as it confirms that the emergence and timing of the EBOLA VIRUS remergence as very real and imminent threat as a possibile airborn pathogen, no expert has gone on record to state anything to the contrary that it could be transmitted a multitude of ways or variables: I believe with BOEING essentially sponsoring the FIREFLY DX EBOLA PATHOGEN DETECTOR by licensing the test kits from PSID with upfront good faith fee payments of 2.5 million to make sure they distribute the FIREFLY DX hand-held testers and subsequently get the lionshare of the future EBOLA virus testing contracts through HOMELAND SECURITY ET AL US MILITARY, AND OTHER GOVT AGENCIES.... Good strategy from CARGOL, their CEO, who is a very smart and savvy strategist for making POSTIVE ID REVENUE INDEFINITELY through royalties and licensing fees for use of MBAND AND FIREFLY DX BY other companies and world wide usage by every country most likely--huge getting revenue on the ledger and POSITIVE ID still has the deferred payment revenue of 2.5 million from BOEING ALREADY PAID but being deferred till end of year 10K report for earning surprise along with an already initial contract for FIREFLY DX TO BE produced and distributed by BOEING (BA) no doubt as a sweetner to future defense contracts for defense and NASA.... FUTURE IS BRIGHT FOR POSITIVE ID (PSID) due to EBOLA scaring the #$%$ out of the whole country....

    Sentiment: Strong Buy

  • should beat expert expectations of eps of (-.01) by a whopping six cents a share with a eps per share of +.05 based on current revenue of almost 500,000.00 and deferred revenue of 2.5 million paid to them in two installments of 1.25 million each by BOEING BA for distribution rights to FIREFLY PSA handheld EBOLA tester and also will owe POSITIVE ID royalty fees for each unit and all refills for retesting etc..... BOEING AND POSITIVE ID ALREADY HAD THEIR EBOLA VIRUS card in play last year and it is just up to Homeland Security and Military to make it official with FDA FASTRACKING THE FIREFLY TESTER DUE TO HOMELAND SECURITY AND FDA ALREADY FAMILIAR WITH MBAND AND FIREFLY PSA H

    Sentiment: Strong Buy

  • Firefly test is by far the quickest, 20 minutes or less, most accurate with very few false positives, and is by far the cheapest test to pay for at 25.00 a test--psid already has agreement in place with boeing which lets boeing distribute the tester, for which positive id receives a roya,lty for each tester sold and produced as well as licensing royalties for the array, contents, and ebola/pathogen database already in place for firefly users to compare to samples of ebola most often contracted.... why waste time?

    Sentiment: Buy

  • So, the eps will certainly beat expert eps estimates--i say they find a way to make it in to the black with +.01 a share eps up from a deficit for last year of -04

    Sentiment: Strong Buy

  • Set to explode as silver is fast overtaking gold as the metal of choice.....

    Sentiment: Buy

  • ZACHS says done deal...

    Sentiment: Buy

  • linsprucker linsprucker Nov 13, 2014 8:24 AM Flag

    you are always wrong.... remember? hope you can get some cheaper huh

    Sentiment: Buy

  • i hope the amateurs jump ship and sell reflexively so i can get shares dirt cheap....))

    Sentiment: Strong Buy

  • linsprucker linsprucker Nov 13, 2014 3:21 AM Flag

    Employees affected by the Restructuring were notified on September 11, 2014 and are being provided with severance arrangements including outplacement assistance. The Company expects to complete the Restructuring during the third quarter of 2014.
    As a result of the Restructuring, the Company expects to record one-time charges with respect to severance payments and benefits continuation, which are estimated to be approximately $0.3 million and are expected to be recorded in the third quarter of 2014. As a result of the Restructuring, the Company estimates it will generate annualized expense savings of approximately $1.9 million primarily from savings in employee salaries and benefits.

    Sentiment: Strong Buy

  • linsprucker linsprucker Nov 13, 2014 3:15 AM Flag

    loss from operations only 400,000 no salary expense or research due to staff being reduced which severance pkgs of 300,000.00 to be written off this qtr and therefore the 1.9 mil salary expense will be zero expense this qtr and next and etc.... therefore revenue should be over 1000 which will make no loss from operations and a positive earnings of .03 a share for this qtr --next qtr double that ,,,,,,

    Sentiment: Strong Buy

  • THOMPSON REUTERS UPGRADED BG MEDICINE FROM NOVEMBER 2013 THROUGH NOVEMBER 2014 OF THIS YEAR PERIOD.... SEEMS THEY WERE SPOT ON,,,,,, HERE IS THE INFO WHICH YOU CAN FIND ON THOMPSON REUTERS SITE AND MOST BROKERS ONLINE....
    DJIA: 17,366.24 -24.28 (-0.14%) | NASDAQ: 4,638.907 +8.166 (0.18%) | S&P 500: 2,017.81 -0.24 (-0.01%) —Markets closed
    Print | Help/Glossary
    Thomson Reuters I/B/E/S Estimates Performance & History: BGMD
    BG MEDICINE INC
    0.48Up 0.0422 (9.64 %)AS OF 4:00:00PM ET 11/03/2014
    Trade Add to Watch List Set Alert Hypothetical Trade Price History down
    PerformanceOpinion History
    BGMD Thomson Reuters I/B/E/S Estimates vs. Stock Performance View Press Alt plus down arrow to view menu options.
    BGMD PRICE S&P 500 RUSSELL 3000
    Rollover Arrows for Details
    Price

    1 Year Thomson Reuters I/B/E/S Estimates Price Performance Opinions
    Period Action From To Period
    Length Price
    Performance S&P 500
    Performance Russell 3000
    Performance
    12/30/2013 - 10/31/2014 Upgrade Buy Strong Buy 305 days -130.70% +8.77% +7.97%

    Sentiment: Strong Buy

  • The company was valued at almost 4.00 a share before the fda added the positives

    Sentiment: Strong Buy

  • they saw all the institutional backers in place and put the stamp of approval on BGMD.....

    Sentiment: Strong Buy

  • linsprucker linsprucker Nov 3, 2014 9:49 AM Flag

    they have a shitload of hedge fund investors who will make sure that the track is greased all the way down hill..... wheeeee....

    Sentiment: Strong Buy

OCLR
1.88+0.01(+0.53%)Dec 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Virgin America Inc.
NASDAQFri, Dec 26, 2014 4:00 PM EST
Moody's Corporation
NYSEFri, Dec 26, 2014 4:01 PM EST